<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>29(4)</volume><submitter>Zhou C</submitter><funding>National Natural Science Foundation of China</funding><pubmed_abstract>Cancer-associated lymphatic endothelial cells (LECs) are an active barrier to the effector arm of the anti-tumor immune response; however, it remains unclear how LECs become immunosuppressive in the tumor microenvironment (TME). Exosomal microRNAs (miRNAs) have recently been implicated in intercellular crosstalk within the TME. Here, we report a mechanistic model via which cervical cancer-secreted, exosome-encapsulated microRNA (miR)-1468-5p promotes lymphatic PD-L1 upregulation and lymphangiogenesis to impair T cell immunity. Subsequently, exosomal miR-1468-5p epigenetically activates the JAK2/STAT3 pathway in LECs by directly targeting homeobox containing 1 (HMBOX1) in the SOCS1 promoter, activating an immunosuppressive program that allows cancer cells to escape anti-cancer immunity. Furthermore, clinical data reveal that high serum exosomal miR-1468-5p levels correlate with TME immunosuppressive status and poor prognosis in cervical cancer (CCa) patients. Taken together, our results suggest that cancer-secreted exosomal miR-1468-5p instructs LECs to form an integrated immunosuppressive TME component and may be a prognostic biomarker and therapeutic target for CCa.</pubmed_abstract><journal>Molecular therapy : the journal of the American Society of Gene Therapy</journal><pagination>1512-1528</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8058488</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Cancer-secreted exosomal miR-1468-5p promotes tumor immune escape via the immunosuppressive reprogramming of lymphatic vessels.</pubmed_title><pmcid>PMC8058488</pmcid><pubmed_authors>Yang Y</pubmed_authors><pubmed_authors>Zhou C</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Wu S</pubmed_authors><pubmed_authors>Liang L</pubmed_authors><pubmed_authors>Ma J</pubmed_authors><pubmed_authors>Wang W</pubmed_authors><pubmed_authors>Wei W</pubmed_authors><pubmed_authors>Chen X</pubmed_authors><pubmed_authors>Huang L</pubmed_authors><pubmed_authors>Wang Z</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cancer-secreted exosomal miR-1468-5p promotes tumor immune escape via the immunosuppressive reprogramming of lymphatic vessels.</name><description>Cancer-associated lymphatic endothelial cells (LECs) are an active barrier to the effector arm of the anti-tumor immune response; however, it remains unclear how LECs become immunosuppressive in the tumor microenvironment (TME). Exosomal microRNAs (miRNAs) have recently been implicated in intercellular crosstalk within the TME. Here, we report a mechanistic model via which cervical cancer-secreted, exosome-encapsulated microRNA (miR)-1468-5p promotes lymphatic PD-L1 upregulation and lymphangiogenesis to impair T cell immunity. Subsequently, exosomal miR-1468-5p epigenetically activates the JAK2/STAT3 pathway in LECs by directly targeting homeobox containing 1 (HMBOX1) in the SOCS1 promoter, activating an immunosuppressive program that allows cancer cells to escape anti-cancer immunity. Furthermore, clinical data reveal that high serum exosomal miR-1468-5p levels correlate with TME immunosuppressive status and poor prognosis in cervical cancer (CCa) patients. Taken together, our results suggest that cancer-secreted exosomal miR-1468-5p instructs LECs to form an integrated immunosuppressive TME component and may be a prognostic biomarker and therapeutic target for CCa.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Apr</publication><modification>2025-04-04T10:17:52.431Z</modification><creation>2025-04-04T10:17:52.431Z</creation></dates><accession>S-EPMC8058488</accession><cross_references><pubmed>33388421</pubmed><doi>10.1016/j.ymthe.2020.12.034</doi></cross_references></HashMap>